GRFS Grifols SA IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1438569 · Reporting currency EUR
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 7.21B | 6.59B |
| Cost of revenue | 4.42B | 4.11B |
| Gross profit | 2.79B | 2.48B |
| R&D expense | 384.04M | 395.28M |
| SG&A expense | 1.26B | 1.37B |
| Operating income | 1.19B | 782.32M |
| Interest expense | 714.76M | 596.88M |
| Pretax income | 444.00M | 207.02M |
| Income tax | 231.19M | 43.35M |
| Net income | 156.92M | 42.32M |
| EBITDA | 1.63B | 1.23B |
| EPS (basic) | 0.23 | 0.06 |
| EPS (diluted) | 0.23 | 0.06 |
| Weighted avg. shares (diluted) | 679.92M | 677.10M |
| Balance sheet | ||
| Cash & equivalents | 979.78M | 529.58M |
| Receivables | 835.60M | 767.26M |
| Inventory | 3.56B | 3.48B |
| Current assets | 5.73B | 6.13B |
| PP&E, netmay include right-of-use assets (IFRS) | 3.34B | 3.25B |
| Goodwill | 7.40B | 6.80B |
| Intangibles | 2.93B | 2.83B |
| Total assets | 21.41B | 20.99B |
| Current liabilities | 2.16B | 2.33B |
| Short-term debt | 318.20M | 674.31M |
| Long-term debt | 2.34B | 3.65B |
| Total debt | 2.66B | 4.32B |
| Total liabilities | 12.80B | 13.48B |
| Shareholders' equity | 5.88B | 5.37B |
| Net debt | 1.68B | 3.79B |
| Cash flow statement | ||
| Operating cash flow | 902.17M | 218.69M |
| Capital expenditure | 232.54M | 224.44M |
| Free cash flow | 669.63M | -5.75M |
| Investing cash flow | 886.67M | -394.72M |
| Financing cash flow | -1.36B | 171.49M |
| Depreciation & amortization | 437.90M | 446.42M |
| Dividends paid | 962,000 | 0 |
| Share buybacks | — | 0 |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.